Vor Biopharma (VOR) Set to Announce Quarterly Earnings on Monday

Vor Biopharma (NYSE:VOR) is scheduled to announce its earnings results on Monday, April 29th.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.10. On average, analysts expect Vor Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vor Biopharma Trading Down 0.6 %

VOR opened at $1.69 on Friday. The stock has a fifty day simple moving average of $2.01 and a two-hundred day simple moving average of $2.11. The company has a market cap of $115.29 million, a price-to-earnings ratio of -0.96 and a beta of -0.36. Vor Biopharma has a 12-month low of $1.62 and a 12-month high of $5.70.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VOR shares. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a report on Tuesday, April 23rd. JMP Securities restated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a report on Thursday, March 21st. Stifel Nicolaus reduced their price target on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 21st. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 price target (down from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.50.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.